A PROSPECTIVE STUDY OF ADVERSE DRUG REACTIONS DUE TO PLATINUM ANALOGS - CHEMOTHERAPY IN A TERTIARY CARE HOSPITAL
Keywords:Adverse drug reactions, Chemotherapy, Causality, Platinum analogs
Objective: The objective of this study was to analyze the types of adverse drug reactions (ADRs) associated with platinum analogs (cisplatin, carboplatin and oxaliplatin) used for cancer chemotherapy in a tertiary care hospital and determine their causal relationship with the offending drug.
Methods: This prospective, observational, non-interventional study was conducted in a tertiary care hospital at GSVM Medical College Kanpur, India, for 4 months. Patients of all age and either sex were included in the study. ADRs were reported by the physicians of oncology department of the hospital and ADRs were assessed for different parameters -causality, outcome, and seriousness of ADR as per the World Health Organization (WHO), type of ADRs as per expanded Rawlins and Thompson's classification, predictability using council for international organization of medical sciences guidelines and severity using modified Hartwig's scale. Descriptive statistics were used for data analysis.
Results: A total of 140 ADRs were reported from platinum analogs following treatment of different types of cancer in hospital. The burden of ADRs in each patient was 2.41. Most of the ADRs were observed in the age group of 40â€“60 years. Vomiting (27 ADRs) was commonly reported reaction. Among platinum analogs, cisplatin leads to 82 ADRs (58.57%) followed by carboplatin with 53 ADRs (37.86%) and least with oxaliplatin 5 ADRs (3.57%). Most of the ADRs on causality assessment were possible (104, 74.29%) and probable (36, 25.71%) in nature. Type -A ADRs account for 4/5th of the total reported ADRs, followed by Type-B and C. Severity of 90.71% ADRs was found to be mild followed by moderate, with no case of severe and serious nature. Nearly, most of the ADRs were of predictable type (97.14%).
Conclusion: The potential of platinum analogs to cause ADRs is high; thus, the need of effective ADRs monitoring is highly emphasized.
Parthasarathi G, Karin N, Milap CN. A Textbook of Clinical Pharmacy Practice, Essential Concepts and Skills. 2nd ed. India: Universities Press Private Limited.; 2012.
Eby M, Chandrika C, Preethy MK, Srinivasa R. A prospective observational study on prescribing trends and adverse drug reactions in stroke patients. Int J Pharm Pharm Sci 2017;9:25-30.
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. B Med J 2004;329:15-9.
Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-28.
Sharwankumar S, Bhaswat C. Safety signal detection for platinum compounds in canadian spontaneous adverse event reports. Int J Pharm Pharm Sci 2017;6:405-11.
Poklar N, Pilch DS, Lippard SJ, Redding EA, Dunham SU, Breslauer KJ. Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex. Proc Natl Acad Sci 1996;93:7606-11.
Rudd GN, Hartley JA, Souhami RL. Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individual. Cancer Chemother Pharmacol 1995;35:323-6.
Katzung BG. Basic Clinical Pharmacology. 10th ed. San Francisco: The McGraw-Hill Companies; 2007.
Tripathi KD. Essentials of Medical Pharmacology.7th ed. New delhi: Jaypee Brothers; 2013.
Couffignal AL, Lapeyre-Mestre M, Bonhomme C, Bugat R, Montastruc JL. Adverse effects of anticancer drugs: Apropos of a pharmacovigilance study at a specialized oncology institution. Therapie 2000;55:635-41.
Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilmanâ€™s. The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw Hill; 2011.
Swathi B. Adverse drug reaction profiles of commonly used platinum compounds in cancer chemotherapy. Int J Basic Clin Pharmacol 2015;4:284-9.
Chopra D, Harmeet SR, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: A prospective observational survey. Indian J Med Paed Oncol 2016;37:42-6.
Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations. Oncology 2007;12:1143-50.
Behera SK, Kishtapati CR, Gunaseelan V, Dubashi B, Chandrasekaran A, Selvarajan S. Adverse drug reactions in cancer patient. Young Pharm 2017;9:593-97.
Sharma A, Kumari KM, Manohar HD, Bairy KL, Thoma SJ. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in South India. Perspect Clin Res 2015;6:109-15.
Saini VK, Sewal RK, Ahmad Y, Medhi B. Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital. Indian J Pharm Sci 2015;77:687-93.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.